Benzinga | Sep 30, 2020 10:59AM EDT

Needham Maintains Buy on CTI BioPharma, Raises Price Target to $6

Needham maintains CTI BioPharma (NASDAQ:CTIC) with a Buy and raises the price target from $3.5 to $6.